PROX1 and liver cancer: Indeed, the PROX1 protein abundance was reduced in response to glucose deficiency, metformin or MK8722 (a selective on-target synthetic AMPK activator) treatment in liver cancer cells and mouse embryonic fibroblasts (MEFs) (Fig. 1e–g and Supplementary Fig. 1d–g).